ADL5859 is a novel, oral compound that targets the Delta opioid receptor. Delta receptor agonists are thought to offer benefits over other approaches to the management of pain.
Investigated for use/treatment in pain (acute or chronic).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.